N-(2-(1H-benzo[d]imidazol-2-yl)phenyl)isobutyramide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-(2-(1H-benzo[d]imidazol-2-yl)phenyl)isobutyramide
• 英文别名: N-[2-(1H-benzimidazol-2-yl)phenyl]-2-methylpropanamide
• 化学式: C₁₇H₁₇N₃O
• 分子量: 279.34
• InChiKey: OLGMRMJENRKJRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Heteroaryl compounds useful as inhibitors of GSK-3
  申请人：——

  公开号：US20040034037A1

  公开（公告）日：2004-02-19

  The present invention relates to compounds of formula I useful as inhibitors of GSK-3 and Lck protein kinases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes, Alzheimer's disease, and transplant rejection.

  本发明涉及式I的化合物，其可用作GSK-3和Lck蛋白激酶的抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了利用这些组合物在治疗和预防各种疾病，如糖尿病、阿尔茨海默病和移植排斥等方面的方法。
• HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3
  申请人：Harbeson L. Scott

  公开号：US20070270420A1

  公开（公告）日：2007-11-22

  The present invention relates to compounds of formula I useful as inhibitors of GSK-3 and Lck protein kinases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes, Alzheimer's disease, and transplant rejection.

  本发明涉及一种公式I的化合物，其可用作GSK-3和Lck蛋白激酶的抑制剂。本发明还提供了包含该发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗和预防各种疾病的方法，例如糖尿病、阿尔茨海默病和移植排斥反应。
• Compounds that enhance Atoh-1 expression
  申请人：MASSACHUSETTS EYE & EAR INFIRMARY

  公开号：EP2732819A2

  公开（公告）日：2014-05-21

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g. a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

  本发明一般提供化合物、药物组合物及其使用方法，其中包括导致生物细胞中 Atoh1 基因（如 Hath1）表达增加的方法。更具体地说，本发明涉及可从 Atoh1 表达增加中获益的疾病和/或失调症的治疗，例如与听觉毛细胞丧失有关的听力损伤或失调症，或与细胞异常增殖有关的失调症。
• Compounds that enhance Atoh1 expression
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：US10406163B2

  公开（公告）日：2019-09-10

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

  本发明一般提供化合物、药物组合物及其使用方法，其中包括导致生物细胞中Atoh1基因（如Hath1）表达增加的方法。更具体地说，本发明涉及可从 Atoh1 表达增加中获益的疾病和/或失调症的治疗，例如，与听觉毛细胞丧失有关的听力损伤或失调症，或与细胞异常增殖有关的失调症。
• Efficient delivery of therapeutic molecules to cells of the inner ear
  申请人：Massachusetts Eye and Ear Infirmary

  公开号：US11370823B2

  公开（公告）日：2022-06-28

  Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

  提供了诱导内耳细胞进入细胞周期和增殖的组合物。特别是，通过服用能激活 Myc 和 Notch 的组合物来诱导毛细胞增殖。通过抑制 Myc 和 Notch 的活性或激活 Atoh1，诱导支持细胞向毛细胞转分化。治疗方法包括在细胞内将这些分子输送到特定的治疗靶点。